Practical Aspects of Immunotherapy

Friday, September 29, 2023

9:45 AM – 11:45 AM EEST

Location: Trianti

Chair(s)

Jesus San Miguel, PhD. MD. (he/him/his)

Director of Clinical & Translational Medicine of University of Navarra
Clínica Universidad de Navarra
Pamplona, Navarra, Spain

Co-Chair(s)

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States

Presentations:

9:45 AM – 9:55 AM EEST

Integrating T cell redirection in frontline MM
Speaker: Adam D Cohen, MD – Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
9:55 AM – 10:05 AM EEST

How do we sequence CART, bispecifics and ADC and other drugs?
Speaker: Niels van de Donk, MD PhD (he/him/his) – Amsterdam UMC
10:05 AM – 10:15 AM EEST

Managing acute immunotherapy complications
Speaker: Krina K. Patel, MD (she/her/hers) – MD Anderson Cancer Center, University of Texas, Houston, TX, USA
10:15 AM – 10:25 AM EEST

Prevention and monitoring of infections with immunotherapies
Speaker: Joshua Richter, MD – Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
10:25 AM – 10:35 AM EEST

OA-07: Phase I Study of BCMA CAR-T Using Instant Manufacturing Platform or Traditional Production Process for Relapsed/Refractory Multiple Myeloma Therapy
Speaker: Hui Liu, LH – Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, China
10:35 AM – 10:45 AM EEST

OA-11: Utility of 18FDG-PET/CT for Risk Prediction in Relapsed/Refractory Multiple Myeloma Patients Undergoing CAR-T Cell Therapy: Analysis of Baseline and Early Assessment Scans After One and Three Months
Speaker: Luis-Esteban Tamariz-Amador, MD – Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IdiSNA
10:45 AM – 10:55 AM EEST

OA-51: Preliminary Recommendations for Prevention and Management of Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab Based on Experience From the MajesTEC-1 Study
Speaker: Niels van de Donk, MD PhD (he/him/his) – Amsterdam UMC
11:00 AM – 11:15 AM EEST

Discuss abstracts in context
Speaker: Noopur Raje, MD – Massachusetts General Hospital Cancer Center
11:15 AM – 11:45 AM EEST

Round table discussion
Panelist: Jesus G. Berdeja, MD – Sarah Cannon Research Institute
Panelist: Ivan Borrello, MD – Tampa General Hospital
Panelist: Tom Martin, MD (he/him/his) – UCSF
Panelist: Monika Engelhardt
Panelist: Sham Mailankody, MBBS – Memorial Sloan Kettering Cancer Center